Get the Stockscreener App
0.5649
7.41%
-0.0452
After Hours:
.54
-0.0249
-4.41%
Onconetix Inc stock is traded at $0.5649, with a volume of 773.61K.
It is down -7.41% in the last 24 hours and up +29.27% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$0.6101
Open:
$0.5568
24h Volume:
773.61K
Relative Volume:
0.09
Market Cap:
$4.69M
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.00519
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
+17.69%
1M Performance:
+29.27%
6M Performance:
-91.49%
1Y Performance:
-93.18%
1-Day Range:
$0.543
$0.5944
1-Week Range:
$0.445
$1.04
52-Week Range:
$0.3155
$21.40
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.5649 | 4.69M | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Onconetix Inc Stock (ONCO) Latest News
Stock market today: Allakos dropped by 76.37% whereas Onconetix jumped by 77.10% in early trading - Business Upturn
Onconetix faces Nasdaq delisting over share price rule - MSN
Onconetix faces Nasdaq delisting over share price rule By Investing.com - Investing.com Nigeria
Onconetix settles with IQVIA, adjusts accounts payable - MSN
Onconetix settles with IQVIA, adjusts accounts payable By Investing.com - Investing.com Canada
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
ONCO Stock Plummets to 52-Week Low at $0.37 Amid Market Struggles By Investing.com - Investing.com South Africa
Onconetix files overdue quarterly report, addresses Nasdaq notice By Investing.com - Investing.com South Africa
Onconetix files overdue quarterly report, addresses Nasdaq notice - Investing.com
Onconetix, Inc. Announces Receipt of Notice from Nasdaq - GlobeNewswire
Onconetix Resolves Nasdaq Compliance Issue After Late Q3 Filing - StockTitan
ONCO stock touches 52-week low at $0.58 amid market challenges - Investing.com India
Onconetix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Onconetix Inc. (ONCO) reports earnings - Quartz
Onconetix amends forbearance agreement with Veru Inc. - Investing.com
ONCO Stock Hits 52-Week Low at $0.6 Amid Market Challenges - Investing.com Nigeria
ONCO stock touches 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $0.99 amid market challenges - Investing.com
SEC Form 424B4 filed by Onconetix Inc. - Quantisnow
Zurcher Kantonalbank's Strategic Acquisition of Onconetix Inc Sh - GuruFocus.com
ONCO stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa
ONCO stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada
Onconetix, Inc. (NASDAQ:ONCO) Sees Large Decline in Short Interest - MarketBeat
Onconetix announces change in certifying accountant - Investing.com India
Onconetix announces change in certifying accountant By Investing.com - Investing.com South Africa
Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update - MarketBeat
Onconetix announces financing through $2M private placement - TipRanks
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C - The Bakersfield Californian
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewswire
Onconetix raises $2 million in private placement - Investing.com
Onconetix Secures Funding to Enhance Operations and Growth - TipRanks
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewswire
Onconetix Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
What's Going On With Onconetix Shares Friday? - MSN
Investing in Onconetix Inc (ONCO) might be a great opportunity, but the stock is a bit overvalued - US Post News
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.20% - MSN
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Onconetix shares go way up on Altos Ventures investment and stock split - Mugglehead
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):